Research programme: tyrosine kinase inhibitor - Ascepion/Debiopharm

Drug Profile

Research programme: tyrosine kinase inhibitor - Ascepion/Debiopharm

Alternative Names: ASP-08126; Debio 1144

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascepion Pharmaceuticals
  • Developer Ascepion Pharmaceuticals; Debiopharm
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in China (PO)
  • 18 Jun 2012 Debio 1144 licensed to Debiopharm worldwide
  • 21 Apr 2010 Preclinical trials in Solid tumours in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top